Enliven Therapeutics, Inc.
ELVN
$27.25
-$0.54-1.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 89.78% | -3.13% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 36.62% | -12.20% | |||
| Operating Income | -36.62% | 12.20% | |||
| Income Before Tax | -47.25% | 20.47% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -47.25% | 20.47% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -47.25% | 20.47% | |||
| EBIT | -36.62% | 12.20% | |||
| EBITDA | -36.77% | 12.17% | |||
| EPS Basic | -46.96% | 33.26% | |||
| Normalized Basic EPS | -46.94% | 33.27% | |||
| EPS Diluted | -46.96% | 33.26% | |||
| Normalized Diluted EPS | -46.94% | 33.27% | |||
| Average Basic Shares Outstanding | 0.19% | 19.17% | |||
| Average Diluted Shares Outstanding | 0.19% | 19.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||